SCHEMBL2161303

SCHEMBL2161303

COC(=O)c1cnc(-c2ccccn2)s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.73
SMN1; SMN2 Q16637 5/20 0.60
RAB9A P51151 4/20 0.60
NPC1 O15118 3/20 0.60
MAPT P10636 3/20 0.60
KDM4E B2RXH2 9/20 0.49
LMNA P02545 2/20 0.48
GAA P10253 1/20 0.48
APOBEC3G Q9HC16 1/20 0.47
KMT2A Q03164 2/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC10 Q969S8 1/20 0.47
HDAC11 Q96DB2 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
HDAC9 Q9UKV0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2160017 0.86 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL1313344 0.84 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3593014 0.84 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL29670209 0.84 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL8284425 0.83 ALDH1A1 (0.70) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL12571410 0.82 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
Hydrochloric Acid SCHEMBL6508481 0.82 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6609203 0.81 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL8562966 0.81 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL30664409 0.81 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526098-B1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-07-11 EP disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
EP-2610244-A1 Indole compounds Ironwood Pharmaceuticals, Inc. (US) 2013-07-03 EP disclosed
US-8470820-B2 Nitrogen-containing heteroaryl derivatives HOFFMAN-LA ROCHE INC. (US) 2013-06-25 US disclosed
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 US disclosed
WO-2011089132-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-07-28 WO disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed
US-20090118503-A1 FAAH INHIBITORS IRONWOOD PHARMACEUTICALS, INC. 2009-05-07 US disclosed
WO-2005075469-A1 THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY ARGENTA DISCOVERY LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075469-A1 THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY ARGENTA DISCOVERY LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 ALDH1A1 1229/4885SMN1; SMN2 3581/4885RAB9A 3562/4885
US-20110183979-A1 NITROGEN-CONTAINING HETEROARYL DERIVATIVES PDE3A, PDE2A, PDE10A ALDH1A1 434/4885SMN1; SMN2 2475/4885RAB9A 298/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT ALDH1A1 178/4885SMN1; SMN2 4663/4885RAB9A 1688/4885
US-20090118503-A1 FAAH INHIBITORS FAAH, FAAH2, CNR2 ALDH1A1 648/4885SMN1; SMN2 4055/4885RAB9A 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.